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Abstract
Background: Cancer of unknown primary remains a mallignancy of elusive biology and grim
prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of
unknown primary to expand our knowledge on the biology of these tumors and identify potential
therapeutic targets.
Methods: Paraffin embedded archival material from 81 patients diagnosed with CUP was used.
Tumor histology was adenocarcinoma (77%), undifferentiated carcinoma (18%) and squamous cell
carcinoma (5%). The tissue expression of CD34, VEGF and TSP-1 was assessed
immunohistochemically by use of specific monoclonal antibodies and was analyzed against
clinicopathological data.
Results: VEGF expression was detected in all cases and was strong in 83%. Stromal expression of
TSP-1 was seen in 80% of cases and was strong in 20%. The expression of both proteins was not
associated with any clinical or pathological parameters. Tumor MVD was higher in tumors classified
as unfavorable compared to more favorable and was positively associated with VEGF and negatively
with TSP-1.
Conclusion: Angiogenesis is very active and expression of VEGF is almost universal in cancers of
unknown primary. These findings support the clinical investigation of VEGF targeted therapy in this
clinical setting.
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Background
Cancer of unknown primary (CUP) is a unique clinical
entity that accounts for an approximately 3% of human
cancers[1]. Patients with CUP present with metastases for
which the site of origin cannot be identified at initial
workup. Early dissemination, unpredictability of meta-
static pattern and aggressiveness constitute fundamental
characteristics of these tumors. Although the clinical char-
acteristics of CUP have been established, little is known
about the underlying biology of these tumors [2,3].
Angiogenesis, the formation of new vessels, is essential for
tumor growth and the development of metastases. It
evolves though a complex multifactor process that
involves interaction of pro-angiogenic and anti-ang-
iogenic signals from tumor, endothelial and stromal cells.
The angiogenic activity is reflected in the development of
novel microvessels in tumor tissue that is quantified by
the intratumoral microvessel density (MVD). Among sev-
eral molecules implicated, Vascular Endothelial Growth
Factor (VEGF) and Thrombospondin-1 (TSP-1) appear to
be most relevant. Much evidence indicates that VEGF is a
key activator of angiogenesis[4,5] and TSP-1 a primary
endogenous inhibitor of angiogenesis[6] Up to now, no
useful prognostic factors have been established other than
the classic pathologic and laboratory ones and immuno-
histochemical detection of various factors did not add
prognostic value in CUP.[7,8] Moreover, investigation of
the expression of crucial angiogenesis factors that can be
therapeutically targeted is today of great interest for the
oncologists who deal with CUP clinical research.[9]
We were prompted to investigate angiogenesis in
unknown primary cancer in an attempt to enrich our
understanding of the biology of these tumors. We studied
by immunohistochemistry the tissue expression of VEGF
and TSP-1 in CUP and correlated with MVD and clinico-
pathological parameters. In a recently published study
vascular endothelial growth factor, and CD34, factors
were not found to be of prognostic value in adenocarci-
noma of unknown primary.[8]
Methods
A total of 81 patients diagnosed with CUP and treated in
three University Medical Oncology Settings (Ioannina,
Patras and AHEPA, Thessaloniki, Greece) between January
1997 and December 2002 were selected on the basis of
availability of archival tumor tissues and accessibility to
medical notes. Pathology diagnosis was reviewed by two
pathologists blinded to written pathology report and rep-
resentative paraffin blocks were selected for
immunohistochemistry.
Subgroup definition
Eligible cases categorized into unfavorable and more favo-
rable subgroups (tables 1 and 2). Patients with poorly dif-
ferentiated carcinoma with midline distribution, papillary
adenocarcinoma of peritoneal cavity and
Table 1: Demographics.
Characteristic No (%)
Patients 81
Sex
Male 39 48
Female 42 52
Age (Years)
Median 66
Range 37–84
PS
Median 1
Range 0–3
Histology
Adenocarcinoma 62 77
Well- and moderately differentiated 27 43
Poorly differentiated 35 57
Undifferentiated carcinoma 15 18
With neuroendocrine features 5 33
Other undifferentiated neoplasms 11 67
Squamous cell carcinoma 4 5
Metastatic sites at presentation
Liver and/or multiple visceral involvement 17 21
Lymph nodes 23 29
Mediastinal-retroperitoneal 17 74
Axillary 2 9
Cervical 4 17
Peritoneal cavity 19 23
Peritoneal adenocarcinomatosis in females 14 74
Malignant ascites and other site 5 26
Lung 5 6
Bones 5 6
Brain 4 5
Neuroendocrine tumors 4 5
Multiple 4 5
Table 2: CUP subsets and outcome.
Subgroups (#) (%)
Favorable 50 62
Unfavorable 31 38
Treatment (#) (%)
Chemotherapy 64 78
Radiotherapy 4 6
Median survival (months)
All cases 10.5
favourable cases 11.5
unfavorable cases 8.5BMC Cancer 2005, 5:25 http://www.biomedcentral.com/1471-2407/5/25
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adenocarcinoma involving only axillary lymph nodes in
women, squamous cell carcinoma involving cervical
lymph nodes and poorly differentiated neuroendocrine
carcinomas were assigned to favorable CUP subsets.
Patients with adenocarcinoma metastatic to the liver,
multiple visceral involvement and extensive metastatic
bone disease were considered as unfavorable.
Systemic chemotherapy was given in 64 patients (78%);
four patients with cerebral metastases received whole
brain irradiation. Chemotherapy was consisted of a plati-
num based combination. Objective response to chemo-
therapy was observed in 34 patients (53%) while one
patient with brain metastases responded to radiotherapy.
Median survival for all patients was 10.5 months (Figure
1). Patients belonging to favorable subsets had a signifi-
cantly higher response rate to treatment (Fisher's t-test, p
= 0.04) and a longer survival, 11.5 vs 8.5 months (p =
0.01).
Immunohistochemistry
Immunostaining was performed on formalin-fixed, paraf-
fin-embedded tissue sections by the labeled streptavidin
avidin biotin (LSAB) method. In brief, tissue sections were
deparaffinised in xylene and dehydrated. They were
immersed in citrate buffer (0,1 m, pH 0,6) and subjected
to microwave twice for 15 min. Subsequently, all sections
were treated for 30 min with 0,3% hydrogen peroxide in
methanol to quench endogenous peroxidase activity.
Mouse monoclonal antibodies directed against human
CD34 antigen (M 7165, Dako) in dilution 1/50 β ) VEGF
Ab-3 (isoform 121, clone Jh121, Neomarkers) in dilution
1/50 and c) thrombospondin (Mob 315, DBS) in
dilution1/50 were used. Positive control slides were
included in all cases. All dilutions were made in TBS-1%
BSA solution and were followed by overnight incubation.
The assessment of immunostaining was made by two
experienced pathologists using light microscope. Tumor
specimens too small to provide sufficient sections for all
the immunoassaying procedures were disregarded from
the study.
Immunostaining evaluation
Staining of endothelial cells for CD34 was used to evalu-
ate the MVD. Any CD34 positive endothelial cell clusters
clearly separated from each other were considered as sin-
gle countable microvessels. A lumen was not required to
identify a vessel. Larger vessels with muscular walls were
excluded from counting. In each sample three areas of
most prominent vascular density (hot spots) were identi-
fied at ×40 power field and microvessel counting was
done under ×400 magnification. Counting was performed
Survival curve of 81 CUP patients analyzed Figure 1
Survival curve of 81 CUP patients analyzed
Table 3: Assessment of tissue expression of VEGF, TSP-1 and CD34.
VEGF TSP-1 MVD (CD34)
Immunostaining score
Median 5 2 59 microvessels/mm2
(range) 2–6 0–3 16–300
Expression intensity (% of cases)
Negative 0 20
Weak 0 30
Intermediate 17 30
Strong 83 20BMC Cancer 2005, 5:25 http://www.biomedcentral.com/1471-2407/5/25
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by two independent observers blinded to clinical infor-
mation. The median count was used to make distinction
between low and high MVD.
Immunoreactivity for VEGF was observed in stromal and
epithelial cells. Only staining of tumor cells was consid-
ered for analysis. To evaluate the expression of VEGF pro-
tein, we devised a combined score that corresponds to the
sum of staining intensity (0 = negative, 1 = weak, 2 = inter-
mediate, 3 = strong staining) and percentile quadrants of
positive cells (0 = 0%, 1 = 1–25%, 2 = 26–50%, 3 =
>50%). The maximum score was 6. Score 2 was regarded
to represent weak expression, score 3 intermediate and
score 4–6 strong expression.
Staining for TSP-1 was only considered in regard to extra-
cellular matrix. The expression of TSP-1 was characterized
according to the extent and the intensity of staining classi-
fied as negative, +1: mild, focal, +2: intermediate, multifo-
cal, +3: strong, diffuse reactivity.
Statistics
Staining results were analyzed against clinical subgroup,
histological differentiation, response to treatment and
survival. The association between MVD and clinical sub-
group, histological differentiation and response to treat-
ment was assessed by an unpaired t test. A Fisher's exact
test was used to determine associations between VEGF
and TSP-1 and the clinical subgroup, histological differen-
tiation and response to treatment. Spearman non para-
metric correlation test was used for associations between
MVD, VEGF and TSP-1.
Survival was calculated by Kaplan-Meier method and
comparison of survival curves was performed by the log-
rank test. For statistical significance a two-tailed p value
was considered. The Graphpad Instat version 3.05
(Graphpad Software, Inc, San Diego, CA) and Prism ver-
sion 4 (Graphpad Software, Inc, San Diego, CA) software
programs were used for statistical analysis and graphing.
Results
Demographics of studied cases are depicted in Tables 1
and 2. Overall survival of patients included in this study is
shown in Figure 1. (Median survival 10 months).
Immunohistochemistry
Microvessel density
Widespread staining for CD34 was seen in all tumor spec-
imens. Within the most prominent vascular areas of the
tumors the recorded mean MVD was 59 microvessels/
mm2 (range, 16 to 300 microvessels/mm2) (Table 3, fig-
ure 2). A positive association was observed between VEGF
expression and MVD (Spearman r = 0.36, p = 0.0016) and
negative with TSP-1.
High-density of neoplastic vessels highlighted by stained anti- CD34 antibody in a case of a poorly differentiated adenocar- cinoma of unknown primary (Original magnification 200,  counterstained with hematoxylin) Figure 2
High-density of neoplastic vessels highlighted by stained anti-
CD34 antibody in a case of a poorly differentiated adenocar-
cinoma of unknown primary (Original magnification 200, 
counterstained with hematoxylin).
Strong cytoplasmic immunohistochemical staining of tumor  cells for VEGF in a CUP case Figure 3
Strong cytoplasmic immunohistochemical staining of tumor 
cells for VEGF in a CUP case. It is shown the characteristic 
granular cytoplasmic staining pattern and the occasionally 
weak positive reaction of intervening stromal and endothelial 
cells (original magnification ×200, counterstained with 
hematoxylin)BMC Cancer 2005, 5:25 http://www.biomedcentral.com/1471-2407/5/25
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VEGF expression
Positive staining of tumor cells for VEGF, both mem-
branic and cytoplasmic was observed in all cases. This was
strong in 83% of the cases and moderate in 17%. VEGF
staining was heterogeneous within tumors comprising of
areas of intense and also weak staining and demonstrated
a characteristic granular cytoplasmic staining pattern.
(Figure 3) A weak and focal positive reaction of interven-
ing stromal cells (fibroblasts or/and macrophage) and
endothelial cells was also seen in some cases. This staining
was excluded from VEGF analysis. (Table 3)
TSP-1 expression
Stromal TSP-1 staining was detected in 80% of the cases,
while in 20% it was absent (figure 4). Strong (score =
3)and intermediate (score = 2) TSP-1 staining was
observed in 50% of cases and weak (score = 1) in 30%
(Table 3). A negative association was observed between
TSP-1 expression and MVD, (Spearman r = -0.3426, p =
0.003) while there was no association between TSP-1 and
VEGF expression.
Association between immunostaining and clinicopathological 
variables
MVD was found statistically higher in unfavorable CUP
cases compared to more favorable ones (70 vs 46 micro-
vessels/mm2, t test, p = 0.034) (table 4). This was the only
correlation detected between angiogenesis related tissue
markers studied and clinicopathological variables. No
association was detected between VEGF and TSP-1 and
tumor differentiation, response to treatment, clinical sub-
groups and survival (Table 4).
Discussion
The investigation of the biological profile of CUP and the
understanding of molecular pathways underlining these
tumors has been limited. We have worked on these issues
and found several oncoproteins overexpressed, but failed
to establish any clinically relevant correlations[10,11]. We
now investigated neo-angiogenesis by assessing MVD and
the tissue expression of two representative molecules
involved in angiogenesis; the major stimulator of angio-
genesis VEGF (A), and the intrinsic angiogenic inhibitor
TSP-1. Overall, we demonstrated that a high angiogenetic
activity occurs in CUP tumors, which is higher in unfavo-
rable when compared with more favorable subsets.
VEGF is known to play a key role and MVD is considered
to reflect the final result of the tumor angiogenesis cas-
cade. In the present study, all cases were found to be
VEGF-positive and in the majority VEGF was overex-
pressed. Tumor VEGF and MVD were strongly correlated
that is in line with findings in solid tumors[12,13]. We
failed to demonstrate any significant correlations of
angiogenic activity with regard to clinical outcome, but
this was obviously due to universal expression of both
CD34 and VEGF in our cases.
We also demonstrated that in our series TSP-1 was overex-
pressed in 50% and was absent or weak in approximately
half of the cases. TSP-1 correlated inversely with microves-
sel counts. The role of TSP-1 in epithelial tumor growth
and metastases remains controversial. In vitro studies sug-
gest that TSP-1 may promote tumor cell adhesion and
invasion by up-regulating urokinase plasminogen activa-
tor and its receptor[14] but  in clinical studies overexpres-
sion has been associated with a lower MVD score and a
better clinical outcome in several carcinomas[15]. Moreo-
ver, other studies suggest that TSP-1 inhibits tumor pro-
gression and may serve as an indicator of less aggressive
potential and of favorable prognosis in solid tumors.[16]
We consider that low TSP-1 in our material reflects a sup-
pression of anti-angiogenic mechanism of TSP-1 that pos-
sibly contributes to the aggressiveness of these tumors.
CUP patients have in general a brief life expectancy with a
median survival approximately of 3–9 months.[17,18] It
must be emphasized that CUP diagnosis applies to a het-
erogeneous group of patients who are usually grouped
together in biological and therapeutic studies to obtain
statistically meaningful results. However several patients
fare better and enjoy longer survival and within this more
favorable prognostic subgroup, unique subsets, such us
young patients with midline tumors and women with
peritoneal carcinomatosis or isolated axillary adenocarci-
Diffuse strong immunoreactivity of extracellular matrix for  TSP-1 adjacent to neoplastic cell population in a CUP case Figure 4
Diffuse strong immunoreactivity of extracellular matrix for 
TSP-1 adjacent to neoplastic cell population in a CUP case. 
(Original magnification ×400, counterstained with 
hematoxylin)BMC Cancer 2005, 5:25 http://www.biomedcentral.com/1471-2407/5/25
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noma, have a distinct clinical biology compared to others
also classified as unknown primary cancer. [19-23]. In our
study MVD score were found low in the group of more
favorable tumors compared to unfavorable, but neither
MVD nor VEGF or TSP-1 were associated with known
prognostic factors.[24] Similarly, Hillen et al, in a small
study, evaluated MVD as a prognostic factor for patients
with liver metastases of unknown primary and found that
MVD score correlated with marginally shorter
survival.[25]
Conclusion
In conclusion, we found that angiogenesis is very active
and VEGF expression is universal in cancer of unknown
primary, which supports the clinical investigation of
VEGF targeted therapy in this clinical setting.[9] To iden-
tify additional druggable molecular targets in cancer of
unknown primary we need to advance our knowledge on
the biology of these tumors and validate novel molecular
therapeutics.
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